HONG KONG – Taiwan-U.S. biopharma company Foresee Pharmaceutical Co. Ltd. has out-licensed its core asset FP-001 (leuprorelin depot) for treating prostate cancer to U.K.-based Accord Healthcare in an $86 million deal.